Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ASPIRA WOMEN'S HEALTH INC.

(AWH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/21/2021 10/22/2021 10/25/2021 10/26/2021 10/27/2021 Date
3.26(c) 3.23(c) 3.26(c) 2.9(c) 3.06(c) Last
137 596 238 809 117 056 757 252 1 167 581 Volume
+1.24% -0.92% +0.93% -11.04% +5.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 7,10 M - -
Net income 2021 -26,7 M - -
Net cash position 2021 55,0 M - -
P/E ratio 2021 -12,0x
Yield 2021 -
Sales 2022 12,0 M - -
Net income 2022 -24,6 M - -
Net cash position 2022 55,0 M - -
P/E ratio 2022 -11,3x
Yield 2022 -
Capitalization 343 M 343 M -
EV / Sales 2021 40,6x
EV / Sales 2022 24,1x
Nbr of Employees 35
Free-Float 52,0%
More Financials
Company
Aspira Women's Health Inc. is engaged in discovering, developing and commercialization of diagnostic and bio-analytical solutions that help physicians to diagnose, treat and improve gynecologic health outcomes for women. Its products include OVA1, Overa and OVA1plus. OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at high-risk... 
More about the company
Ratings of Aspira Women's Health Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ASPIRA WOMEN'S HEALTH INC.
10/07ASPIRA WOMEN HEALTH : Genoox and Aspira Women's Health Inc. Partner to Develop and Deliver..
AQ
10/07Genoox and Aspira Women’s Health Inc. Partner to Develop and Deliver Data-Driven Insigh..
CI
10/01ASPIRA WOMEN HEALTH : Black Women's Health Imperative Lead Congressional Briefing
PU
09/30ASPIRA WOMEN HEALTH : Black Women's Health Imperative Lead Congressional Briefing
AQ
09/29ASPIRA WOMEN HEALTH : Executes Four Aspira Synergy Technology Transfer Agreements
PU
09/29ASPIRA WOMEN HEALTH : Executes Four Aspira SynergyTM Technology Transfer Agreements
AQ
09/29Aspira Women’s Health Executes Four Aspira Synergy Technology Transfer Agreements
CI
09/21Aspira Women's Health Inc. to Present at the Cantor Fitzgerald Virtual Global Healthcar..
GL
09/20ASPIRA WOMEN'S HEALTH INC.(NASDAQCM : AWH) dropped from S&P Healthcare Equipment Select In..
CI
09/09ASPIRA WOMEN HEALTH : Kicks Off Ovarian Cancer Awareness Month by Further Establishing Its..
AQ
08/12ASPIRA : Q2 Earnings Snapshot
AQ
08/12ASPIRA WOMEN HEALTH : Q2 Loss Widens Even as Revenue Jumps
MT
08/12ASPIRA WOMEN HEALTH : HEALTH INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
08/12ASPIRA WOMEN HEALTH : Earnings Flash (AWH) ASPIRA WOMEN'S HEALTH Posts Q2 Revenue $1.8M, v..
MT
08/12ASPIRA WOMEN HEALTH : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
More news
News in other languages on ASPIRA WOMEN'S HEALTH INC.

- No features available -

More news
Analyst Recommendations on ASPIRA WOMEN'S HEALTH INC.
More recommendations
Chart ASPIRA WOMEN'S HEALTH INC.
Duration : Period :
Aspira Women's Health Inc. Technical Analysis Chart | AWH | US04537Y1091 | MarketScreener
Technical analysis trends ASPIRA WOMEN'S HEALTH INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,06 $
Average target price 12,00 $
Spread / Average Target 292%
EPS Revisions
Managers and Directors
Valerie Barber Palmieri President, Chief Executive Officer & Director
Robert Beechey Chief Financial Officer
James T. LaFrance Chairman
Lesley Northrop Chief Scientific Officer
Justin DeGrazia Senior Director-Research & Development
Sector and Competitors